Similarly, engineering NSCs to express higher levels of chemokine receptors, such as CXCR4 and c-Met, augments their responsiveness to tumor-derived chemotactic signals (e.g., CXCL12, hepatocyte growth factor), thereby enhancing tumor tropism (Kumar et al. 2024). This evidence concerns the gene MET and neoplasm.